What’s Hot & What’s Not in Antibody-Drug Conjugates (ADC) Licensing
Antibody-Drug Conjugates combine the specificity of the antibody recognizing the antigen target with the potent tumor-killing effects of a cytotoxic, attached typically via a linker. 6 ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by 2024 (GlobalData). Currently, aboutย 100 ADCs are in clinical development.
This whitepaper addressedย the following questions, among others:
- What targets are suitable?
- What are the trends in linkers and the drugs to be attached to the antibodies? What are the indications being pursued?
- How are companies dealing with the complexities of internalization and high cost of goods? What kind of data will drive an ADC licensing deal?
- How do the ADCs fit in the world of immuno-oncology?
- What is the future for ADCs?
The virtual discussion wasย moderated by biopharma partnering expert,ย Linda Pullan, PhD, of Pullan Consulting along withย Jeff Bockman, PhD, the EVP and Head of the Oncology Practice for Cello Health BioConsulting, formerly Defined Health. The panel featured ADC experts who provided unique insight and a look into the challenges and future of ADCs.